When assessing tumor-specific T cells, all therapies trended towards increased similar levels of tumor-infiltrated AH1-specific CD8+ T cells, which have led to protective antitumor responses in many BALB/c originating tumors [30, 31]. This evidence concerns the gene CD8A and neoplasm.